X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.fiercepharma.com/pharma/seeking-cheaper-generics-colombia-plots-compulsory-license-viivs-hiv-med-dolutegravir
https://endpts.com/gsks-viiv-to-lean-on-long-acting-hiv-portfolio-ahead-of-dolutegravir-patent-expiration/
https://www.prnewswire.com/news-releases/viatris-announces-us-fda-tentative-approval-of-a-paediatric-formulation-of-abacavir-abcdolutegravir-dtglamivudine-3tc-a-once-daily-treatment-for-children-living-with-hiv-301917144.html
https://www.ema.europa.eu/en/documents/overview/dovato-epar-medicine-overview_en.pdf
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216470
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-abacavir-sulfate-dolutegravir-and-lamivudine-tablets-52927.pdf
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/lupin-gets-tentative-usfda-nod-for-dolutegravir-emtricitabine-and-tenofovir-alafenamide-tablets/articleshow/97482041.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214544
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213120
https://www.ema.europa.eu/en/documents/overview/dovato-epar-medicine-overview_en.pdf
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/diabetes-patented-tb-hiv-drugs-enter-essential-list/articleshow/94185393.cms
https://www.globenewswire.com/news-release/2022/06/09/2459524/0/en/Exavir-Therapeutics-announces-publication-of-preclinical-data-for-ultra-long-acting-dolutegravir-prodrug-XVIR-120.html
https://news.bloomberglaw.com/health-law-and-business/fda-approves-viivs-triumeq-pd-for-children-with-hiv?context=search&index=12
https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-us-fda-approval-of-triumeq-pd-the-first-dispersible-single-tablet-regimen-containing-dolutegravir-a-once-daily-treatment-for-children-living-with-hiv/
https://www.reuters.com/business/healthcare-pharmaceuticals/gsk-announces-125-bln-settlement-between-viiv-healthcare-gilead-2022-02-01/
https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-submits-fda-application-for-first-dispersible-single-tablet-regimen-containing-dolutegravir-dtg-for-children-living-with-hiv/
https://www.fiercebiotech.com/biotech/shionogi-licences-third-gen-hiv-asset-ultra-long-dosing-prospect-from-its-partly-owned
https://www.who.int/news/item/08-09-2021-prep-updates-and-new-products-at-ias-2021
https://www.reuters.com/article/us-aids-children/hiv-generic-drug-for-babies-distributed-in-africa-says-unitaid-idUSKCN2EA051
https://www.fda.gov/drugs/human-immunodeficiency-virus-hiv/food-and-drug-administration-approved-revisions-triumeq-abacavirdolutegravirlamivudine-and-dovato
http://www.pharmafile.com/news/568720/viiv-gets-eu-approval-childrens-hiv-treatment
https://viivhealthcare.com/en-gb/media/press-releases/2021/january/viiv-healthcare-receives-eu-marketing-authorisation/
http://www.pharmatimes.com/news/eu_approval_for_viivs_tivicay_for_children_living_with_hiv_1361245
https://www.europeanpharmaceuticalreview.com/news/139197/pfizer-covid-19-vaccine-set-to-generate-sales-of-30-billion/
http://www.pharmafile.com/news/568720/viiv-gets-eu-approval-childrens-hiv-treatment
https://www.prnewswire.com/news-releases/viatris-inc-announces-fda-tentative-approval-of-a-pediatric-formulation-of-dolutegravir-dtg-under-pepfar-301179208.html
https://www.europeanpharmaceuticalreview.com/news/130551/study-suggests-dolutegravir-is-the-optimal-first-line-hiv-medication/
https://www.europeanpharmaceuticalreview.com/news/129913/dolutegravir-plus-lamivudine-shows-non-inferior-hiv-1-suppression-in-phase-iii-trials/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209565
https://www.clinicaltrialsarena.com/news/viiv-dovato-hiv-1-data/
https://extranet.who.int/prequal/news/sun%E2%80%99s-dolutegravir-50mg-tablet-prequalified
https://www.reuters.com/article/us-gsk-viiv-fda-hiv/u-s-fda-approves-gsk-units-drug-to-treat-infants-and-children-with-hiv-idUSKBN23J2XF
https://www.pharmaceutical-technology.com/news/viiv-fda-approval-tivicay-children/
http://www.pharmatimes.com/news/us_approves_first_dispersible_tablet_formulation_of_tivicay_1342268
https://www.fiercepharma.com/marketing/gsk-viiv-s-dovato-wins-fiercemadness-dtc-ad-tournament-closest-contest-yet
https://www.biopharmadive.com/news/gsks-hiv-two-drug-strategy-challenges-gilead/569852/
https://www.fiercepharma.com/marketing/roche-ms-med-gsk-hiv-drug-new-tv-ads-top-november-charts-abbvie-humira
https://www.fiercepharma.com/marketing/gsk-s-viiv-launches-first-campaign-for-new-hiv-med-dovato-real-patients-who-are-more-than
https://www.fiercebiotech.com/biotech/20-year-gsk-veteran-takes-up-cso-role-at-metabolic-startup-hemoshear
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-challenge-of-dovato-211994-dolutegravir-sodium-and-lamivudinetablets-50-mg300-mg-1569474246.pdf
Market Place
Share 
